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Introduction
This paper presents data from the European Surveillance of Antimicrobial Consumption (ESAC) project and reports on the use of cephalosporins in 2009, comprising 45 substances assigned to the Anatomical Therapeutic Chemical (ATC) group J01D and grouped into four generations based on their spectrum of antimicrobial activity (Table 1) . 1, 2 It also reviews temporal trends, the seasonal variation and composition of outpatient cephalosporin use on data collected for the 1997 -2009 period from 33 European countries.
Methods
In 2009, 35 countries were included in the ESAC project, of which 33 countries provided valid data. The methods for collecting use data on # The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com J Antimicrob Chemother 2011; 66 Suppl 6: vi25 -vi35 doi:10.1093/jac/dkr455 vi25 systemic antibiotics were described in the introductory paper of this series. 3 For a detailed analysis, i.e. temporal trends (n ¼31 countries), seasonal variation (n¼27 countries) and the changes in composition of outpatient cephalosporin use (n¼31 countries), we distinguished between first-generation (J01DB), second-generation (J01DC), third-generation (J01DD) and fourth-generation cephalosporins (J01DE). 4, 5 For the period 1997-2009, data on outpatient antibiotic use, aggregated at the level of the active substance, were collected in accordance with the ATC classification and defined daily dose (DDD) measurement unit (WHO, version 2011) . 6 Outpatient antibiotic use data for the year 2009, expressed in DDD per 1000 inhabitants per day (DID), were available for 32 European countries (including Cyprus and Lithuania who provided total use data). For complementary reasons, data for Switzerland (only for the year 2004) are presented as well. Besides the DID outcome measurement unit, the number of packages/1000 inhabitants/day (PID) was utilized (n¼17 countries). Package data have been available since 2006. The calculated DID/PID ratio allows assessment of the number of DDD available per package.
Results

Outpatient cephalosporin use in 2009
The WHO Collaborating Centre for Drug Statistics Methodology has assigned 45 unique ATC codes for cephalosporins; compared with the previous description of outpatient cephalosporin use in Europe, 2 one of these 45 cephalosporins is a newly introduced second-generation substance, three are new third-generation substances and one is a fourth-generation substance. Ten cephalosporins represented 97.0% of total outpatient cephalosporin use in Europe in 2009: cefuroxime (57.4%), cefalexin (10.1%) , cefaclor (9.6%), cefixime (6.9%), cefprozil (4.1%), cefpodoxime (2.9%), cefadroxil (2.6%), ceftriaxone (1.4%), ceftibuten (1.0%) and cefazolin (1.0%). Other substances represented ,1% of total outpatient cephalosporin use. No use was recorded for 15 cephalosporin substances (Table 1) .
Cephalosporins represented 11.4% of total outpatient use of antibacterials for systemic use in 2009. Figure 1 shows total outpatient cephalosporin use expressed in DID subdivided into the four cephalosporin generations in 2009 for 33 European countries, including two countries (Cyprus and Lithuania) with total use data and the Swiss 2004 data. Outpatient cephalosporin use varied by a factor of 267 between the countries with the highest (8.7 DID in Greece) and lowest (0.03 DID in Denmark) use ( Table 2) .
The first-generation cephalosporins represented 14.6% of total European outpatient cephalosporin use. A large variation in outpatient first-generation use was found, ranging from 2.2 DID in Finland to 0.004 DID in Slovenia ( Table 2 ). The highest proportional first-generation use within total cephalosporin use was found for Norway (96.5%). First-generation cephalosporins represented .50% of the total outpatient cephalosporin use in six countries. Their use was mostly represented by just one substance, namely cefalexin (J01DB01), in Norway (96.4% or 0.1 DID), Finland (94.4% or 2.2 DID), the UK (74.6% or 0.4 DID) and Iceland (69.4% or 0.2 DID). Cefadroxil (J01DB05) was most used in Sweden (73.7% or 0.2 DID) and Latvia (27.1% or 0.1 DID). Cefradine (J01DB09) was most used by Ireland (12.7% or 0.2 DID), the UK (8.3% or 0.05 DID) and Portugal (5.5% or 0.1 DID). Minor use of first-generation cephalosporins was reported by France, Germany, Greece, Hungary, Italy, Luxembourg, Malta, Slovenia and Spain (,5% of their total outpatient cephalosporin use). Versporten et al.
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The second-generation cephalosporins represented 71.3% of total European outpatient cephalosporin use. Second-generation use ranged from 8.3 DID in Greece to 0.0003 DID in Norway ( Table 2 ). The highest proportional second-generation use was observed for Luxembourg (96.7%). The second-generation cephalosporins were most frequently used in 20 countries (.50% of total outpatient cephalosporin use). Their use was mostly represented by cefuroxime (J01DC02) for Belgium (90.3% or 1.6 DID), Luxembourg (90.2% or 3.9 DID), Malta (85.2% or 4.7 DID), Poland (82.9% or 2.4 DID), Israel and Slovakia (78.4% and 74.5%, both 3.1 DID), the Czech Republic (70.0% or 1.1 DID) and Cyprus (67.9% or 4.3 DID, total care data). Greek use was mainly represented by cefuroxime (57.9% or 5.0 DID) and cefaclor (J01DC04) (20.6% or 1.8 DID). Ireland had the highest proportional use of cefaclor (57.4% or 0.76 DID). Countries with the highest cefprozil (J01DC10) use were Greece (16.0%), Estonia (14.8%), the Czech Republic (12.4%) and Hungary (11.4%) . Greece was the only country using ceforanide (J01DC11).
The third-generation cephalosporins represented 14.0% of total outpatient cephalosporin use in Europe (mainly cefixime and cefpodoxime), of which 14.3% was for parenteral use (mainly ceftriaxone). Except for Iceland, all countries used thirdgeneration cephalosporins in 2009 ( Table 2 ). The most frequently used fourth-generation cephalosporin was cefepime. Austria and Bulgaria prescribed cefpirome as well. Figure 2 shows total outpatient cephalosporin use expressed in PID for 17 countries for the year 2009 (Italy, 2008 data; Ireland and the Czech Republic, 2007 data) . Italy prescribed the most cephalosporin packages (3.2 PID), followed by Greece, the Russian Federation and Lithuania (1.5, 1.0 and 0.7 PID). Lowest PID figures were found for Denmark and the Netherlands (,0.01 PID), followed by Sweden (,0.05 PID). According to the ranking shown, the Russian Federation shifted from position 13 in DID (low-prescribing country) to position 3 in PID (highprescribing country) and Belgium from position 8 in DID to position 13 in PID. The ranking was similar for Austria, Denmark, Slovenia, Sweden and the Netherlands. Consequently, the lowest mean DDD per package was found in the Russian Federation (0.5 DDD/package) and the highest in Belgium (12.6 DDD/ package), followed by Slovenia and Portugal (7.1 and 6.7 DDD/ package, respectively) . The mean number of DDD for a cephalosporin package in all countries was considerably lower compared with the overall mean number of DDD for an antibiotic package (J01), except for Belgium and Slovenia. In the Russian Federation, Lithuania and Italy, the mean number of DDD per package was 6, 3.5 and 2.8 times lower compared with the mean DDD of total J01 use. - - Longitudinal data analysis (1997 -2009) For Europe, a non-significant increase in total outpatient cephalosporin use of 0.007 (SD 0.009) DID per quarter was found, starting from 1.85 (SD 0.51) DID in the first quarter of 1997, but there was significant seasonal variation with an amplitude of 0.59 (SD 0.11) DID, which decreased significantly over time by 0.003 (SD 0.001) DID per quarter ( Figure 3) . Furthermore, the longitudinal analysis showed that the winter peak of outpatient cephalosporin consumption shifted significantly from one year to another and that there was a positive correlation between the volume of use and the seasonal variation. This means that, in terms of absolute amount, high and low cephalosporin-consuming countries tend to have high and low seasonal variation in cephalosporin use, respectively. Table 2 provides an overview of outpatient cephalosporin use for all 33 participating European countries between 1997 and 2009. Total outpatient use of cephalosporins increased for half of the participating countries. The highest continuous increase since first participation was observed in Germany (with a rise of 154% from 0.9 to 2.4 DID), followed by Slovakia (with a rise of 111% since 1999 from 2.0 to 4.1 DID), Malta (with a rise of 86% since 2007 from 3.0 to 5.5 DID), Bulgaria (with a rise of 67% since 1999 from 1.4 to 2.3 DID), Lithuania (total care use, with a rise of 45% since 2006 from 0.9 to 1.3 DID) and Greece (with a rise of 39% from 6.3 to 8.7 DID). The Russian Federation, however, a low-prescribing country, almost tripled its use from 2003 to 2009, from 0.15 to 0.47 DID; this was mainly the result of the rise in third-generation substances (ceftriaxone, cefixime and cefotaxime). The increase in cephalosporin use for the other countries (Croatia, Cyprus, Estonia and Israel) was mainly the result of the rise in second-generation substances (cefuroxime and cefaclor).
Fourteen countries decreased their overall outpatient cephalosporin use. The highest decrease was observed for Belgium. Minor decreases in overall outpatient cephalosporin use were observed for France, Hungary, Iceland, Ireland, Italy, Latvia, Luxembourg, Portugal, Spain and the UK. Denmark and the Netherlands had the lowest use in absolute numbers (on average in time 0.03 DID and ,0.2 DID, respectively). Use in the Netherlands decreased 3-fold (from 0.13 in 1997 to 0.04 DID), mainly due to the continuous decrease in the secondgeneration cephalosporin cefaclor.
Fourth-generation cephalosporins were prescribed in 24 countries during the period 1997 -2009. However, Estonia, Hungary, Israel, Latvia, Luxembourg, the Netherlands, Poland, Sweden and the UK discontinued their use over time. Denmark, Iceland, Ireland, Norway, Portugal and Slovenia have never prescribed fourth-generation cephalosporins.
Figures S1 and S2 (available as Supplementary data at JAC Online) show the seasonal variation of outpatient cephalosporin use in 27 European countries that were able to provide quarterly data. Seasonal variations were observed in all countries, except for the lowest prescribing countries, Denmark and the Netherlands. The seasonal variation was less pronounced or absent in the low-prescribing countries Iceland, Slovenia, Sweden and UK. Finland also showed a lower seasonal variation compared with the higher prescribing countries.
Compositional data analysis (1997 -2009) For Europe, the relative use of first-generation cephalosporins significantly decreased over time with respect to the second-, third-and fourth-generation cephalosporins (Table 3) .
Proportional use of first-generation cephalosporins decreased by ≥50% in Bulgaria (mainly cefalexin and cefazolin) and Slovakia, by ≥40% in Lithuania (mainly cefazolin), by ≥30% in France (mainly cefaloxin and cefadroxil), Greece (mainly cefadroxil), Luxembourg (mainly cefatrizine, no use in 2009), the Russian Federation (no absolute decrease) and Slovenia (mainly cefalexin), by ≥20% in Croatia, Estonia (cefazolin and no use of cefalexin since 2007) and Poland, and by .10% in Belgium, the Czech Republic (mainly cefalexin, no use in 2009), Germany, Hungary and Latvia (mainly cefalexin). This decrease was matched by increasing use of second-generation cephalosporins (mainly cefuroxime) in all these countries, except for France, where the decrease was compensated by an equal increase in the use of third-generation cephalosporins (mainly the oral cefpodoxime). The decrease in Belgium was mainly related to an overall decrease in cephalosporin use.
Proportional use of first-generation cephalosporins increased by 50% in Iceland by the single use of cefalexin at the expense of the use of cefuroxime. Proportional use of firstgeneration cephalosporins increased by .10% in Finland and the UK (mainly cefalexin). This increase coincided with a L i t h u a n i a C r o a t i a B u l g a r i a F i n l a n d I r e l a n d A u s t r i a P o r t u g a l E s t o n i a C z e c h R e p . B e l g i u m S l o v e n i a S w e d e n N e t h e r l a n d s D e n m a r k In most countries with the highest proportions of firstgeneration cephalosporin use, this proportion continued to increase (Finland and Sweden). Also, Iceland substantially increased the use of first-generation cephalosporins. In countries with the lowest proportions of first-generation use, this proportion further decreased ( Figure S3 , available as Supplementary data at JAC Online).
Second-generation cephalosporin use increased by .70% in Slovakia due to the 9-fold increase in cefuroxime at the expense of cefalexin use. The use of second-generation cephalosporins increased by .20% in Bulgaria (since 2006), Estonia, Germany, Greece (5-fold increase in cefuroxime), Luxembourg and Poland (mainly cefuroxime). This coincided mainly with a drop in cefalexin, cefazolin or cefadroxil. A proportional increase in the use of third-generation cephalosporins was observed for France (mainly cefpodoxime and cefixime) and Italy (mainly ceftriaxone and cefpodoxime) and coincided with a decrease in the use of first-and second-generation cephalosporins in France and Italy, respectively. Austria, Cyprus, Ireland, Israel, Malta, Norway and Portugal showed minor changes in proportional use of the different generations of cephalosporins (≤10%) over time. Norway did not introduce second-and third-generation cephalosporins until 2006 and their use is still marginal.
Discussion
Overall, European outpatient cephalosporin use significantly increased between the first quarter of 1997 and the last of 2009 by 0.36 (SD 0.47) DID, mainly due to the proportional and absolute increases in second-, third-and fourth-generation cephalosporins in most countries. Seasonal variation of cephalosporin use, however, decreased significantly over time.
Various overall trends in cephalosporin use were observed. The high cephalosporin-consuming countries Greece and Malta continued to increase their use. Moreover, the highest sudden increase was observed for Malta, where use almost doubled in only 2 years (from 3 DID in 2007 to 5.5 DID in 2009) . A considerable increase was observed also for Slovakia and Germany. However, Since our first observations in 1997, administration of the first-generation cephalosporin cefazolin increased to 1% of total European cephalosporin use. However, since 1997, the use of the older (narrow-spectrum) cephalosporins decreased in favour of the newer (i.e. broad-spectrum) cephalosporins in most countries. All countries used second-generation cephalosporins. An increase in second-generation use (mainly cefuroxime and cefaclor) by .20% occurred in six countries, while in Slovakia use increased by 70% due to the large increase in the use of cefuroxime. Observed increases in the use of higher generations of cephalosporins were due not only to the proportional decrease in use of first-generation cephalosporins (mainly cefalexin) but also to the absolute increase in the use of more extendedspectrum cephalosporins. Only a few countries consumed significant proportions of third-generation cephalosporins, and their use increased over time. High proportions of parenterally administered substances were observed for Italy, France and the Russian Federation (mainly ceftriaxone). Outpatient parenteral cephalosporin treatment is particularly common in Italy. 7 Ceftriaxone use increased continuously in Italy, and its use almost doubled since the first observation in 1997. A large percentage of the antibiotic courses were given intramuscularly, albeit with the convenience of once-daily administration due to its prolonged half-life. In addition, clinical outcomes were excellent, and patient and physician satisfaction was found to be high. 8 -10 First-generation cephalosporins are predominantly active against Gram-positive bacteria. Successive generations, however, have shown increased activity against Gram-negative bacteria. They are used to treat a wide variety of bacterial infections, including respiratory tract infections, skin infections and urinary tract infections. Given the observed increase in use of oral secondgeneration (mainly cefuroxime) and third-generation (cefixime and cefpodoxime) cephalosporins, the appropriateness of their use should be questioned. Cephalosporin use has been increasing for the treatment of uncomplicated respiratory tract infections with a presumed aetiology, despite no recommendation for cephalosporin use in such circumstances. 11, 12 Drug utilization studies could provide valuable data on the usage of particular drugs.
The extreme variations between countries and over time suggest that cephalosporins, in particular the more extendedspectrum cephalosporins, are inappropriately used to a large extent. In Austria, for example, a continuous and steep increase in the percentage of invasive E. coli isolates resistant to thirdgeneration cephalosporins was observed from 2001 to 2007 (from 0.0% to 8.8%). The increased use of fluoroquinolones 13 and the traditionally frequent use of oral third-generation cephalosporins ( Figure 1 ) may have contributed to the emergence of resistant microorganisms in Austria. 14 As described in the other papers of this series, remarkable differences in volume of use were observed, depending on the outcome measurement unit used (DID or PID). The mean DDD in one cephalosporin package was low in the Russian Federation and considerably higher in Belgium. Consequently, the Russian Federation had a higher cephalosporin use when expressed in PID (1.0) and a lower use when expressed in DID (0.5) compared with Belgium (0.2 PID and 1.8 DID respectively). Therefore, for future surveillance we suggest that the PID and DID outcome measures are compared with each other.
In conclusion, the trends in time and the shift between generations in cephalosporin use in Europe need further exploration. These ESAC results can be used as a historical reference to gauge future interventions to optimize prescribing, and call for future research to gain a deeper understanding of antibiotic use, and cephalosporin use in particular.
